Back to search
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) trials you may qualify forThe MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM…
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Eva…
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy…
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participa…